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ABSTRACT
Alzheimer’s disease is the most prevalent form of dementia and is
characterized by the presence of beta-amyloid plaques and tau tangles. Thioflavin-T, a
fluorescent molecule, is known to have a high binding affinity to beta-amyloid. The
high binding association is optimal for use as an affinity tag in the synthesis of
targeted molecular imaging probes for detection by hyperpolarized
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Xe MRI. An

effort to move away from gadolinium-based contrasts for MRI is at the forefront of
research due to evidence of toxic gadolinium build up in numerous organs. The goal of
this project was to synthesize six Thioflavin-T analogues that could have greater
binding associations and potentially be used to construct xenon probes. The six
analogues were synthesized.
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CHAPTER 1

INTRODUCTION

Alzheimer’s disease (AD) is the most common form of dementia and the most
prevalent neurodegenerative disease.1,2 Dementia is a disease of aging and greatly
affects the geriatric population of 65 and older.3 Of this elderly population 11% are
AD patients.3 Aside from aging, risk factors for AD include gender, low education
levels, smoking, heart disease, stroke, high blood pressure, diabetes, obesity, and
concussions resulting in loss of consciousness specifically for men.4,5 While AD
cannot be definitively diagnosed until post mortem, criteria for a clinical diagnosis
includes cognitive decline in memory, reasoning, visuospatial skills, and language,
and changes in personality and behavior.6,7 Clinicians also use imaging techniques
such as PET, CT and MRI scans to rule out other etiologies when a patient reports a
complaint of cognitive decline.3
The pathophysiological hallmarks of AD are beta-amyloid plaques,
neurofibrillary tau tangles, and neuronal atrophy.8 While, AD has a number of
histopathological factors, beta-amyloid plaques are the focus of this thesis. Amyloid
fibrils are characterized as insoluble protein materials.9 They are a hallmark of chronic
and neurodegenerative diseases beyond AD; which include Parkinson’s disease and
type II diabetes.10-13 Beta amyloid has been shown to be involved in triggering
synaptic dysfunction, regiospecific neuronal death, and loss of neural connectivity.14
Amyloid plaques are made of 39 to 43 amino acid peptide sequences of the amyloid
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beta (Aβ) protein.15 Aβ is a section of the amyloid precursor protein (APP).15 The Aβ
peptide is found in two locations on APP: the C-terminus of the extracellular domain
and the transmembrane domain.15 The production of Aβ requires multiple proteases:
α-secretase, β-secretase, and γ-secretase.15 α-secretase severs APP in the middle which
halts the production of Aβ that would result in disease onset. β-secretase slices APP at
the N terminus of Aβ and γ-secretase cuts APP at the C terminus.15 γ-secretase is
essential for a number of cell signaling cascades.15 γ-secretase produces Aβ of varying
lengths with the prominent being 40 and 42 amino acids.15 Due to the greater number
of hydrophobic residues, Aβ42 has a statistically higher chance of aggregation than
Aβ40.
Thioflavin T (ThT) (Figure 1) is a fluorescent molecule and is the gold
standard for staining and identifying beta-amyloid fibrils which dates back to the late
1950’s.16 ThT binds to the divots along the surface of the fibrils.16 Upon binding to
the fibrils, the ThT fluorescence intensity signal dramatically increases.9

Figure 1: Structure of ThT
The increase in the fluorescence intensity is due to the lack of rotation between
carbon-carbon bond between the benzylamine and benzothiole rings.9,

10, 16

The

restriction in rotation maintains the excitation since unbound ThT has a low energy
threshold and thus free rotation which dampens the excited states from photon
excitation.9 Although ThT has a high affinity to beta amyloid, many groups have
2

synthesized ThT analogues with comparable association constants such as Jung et al.2
The best association constants of the Jung group are 3.27 µM, 6.03 µM, and 7.33 µM.2

Figure 2: Anatomy of Xe biosensor
The importance of ThT in the greater application of this thesis is to be used in
conjunction with supramolecular complexes and Hyperpolarized (HP) xenon (Xe)
magnetic resonance imaging (MRI). Supramolecular complexes (Figure 2, provided
by lab mate A. Fernando) such as rotaxanes, pillararenes, and cyclodextrin are all cage
molecules that have the potential to serve as Xe probes by forming binary or ternary
complexes by encapsulating the noble gas.17 The xenon-129 molecular probe would
contain a linker joining the molecular cage with the targeting molecule.17 We envision
that ThT would be an excellent small molecule for targeting beta-amyloid. In the case
of a rotaxane probe an alkyl chain linker would be threaded through a macrocyclic
cage, where it would be able to participate in non-covalent bonding with the host’s
cavity, creating a pocket to capture Xe.17 The xenon that is encapsulated could then be
selectively detected using a modified MRI instrument.

3

Magnetic resonance imaging (MRI) is the medicinal application of Nuclear
Magnetic Resonance (NMR). MRI is an imaging technique that permits excellent
spatial and temporal images of anatomy without the use of radiation.18 MRIs are able
to image the body through the use of magnetic fields, typically detecting the protons in
water contained in all tissues of the body.18 The magnetic field applied by the MRI
instrument forces the magnetic moments of the protons in the tissues to align with the
applied field, and when a radiofrequency is discharged to the body it causes the
protons to misalign.18 Once the radiofrequency is terminated the protons return to the
magnetic influenced orientation which releases energy and produces a signal that can
be converted into three-dimensional images.18
MRI data that have been acquired with the assistance of molecular contrast agents
often provide sharper images, leading to better clinical application. Contrast agents
improve imaging by altering the relaxation times of the protons, which in turn
heightens contrast in the images.18 The most widely used contrasting agents are
gadolinium-based and have been medicinally used for over 30 years.19 The initial
safety profile of the gadolinium agents were not alarming apart from patients with
renal failure who would develop nephrogenic systemic fibrosis upon contrast agent
exposure.19 However, as gadolinium contrasting agents continued to be used in
diagnostic MRI, adverse effects and toxicity have been reported, and warnings and
restrictions by the U.S Federal Drug Administration and European Medicines Agency
have been issued.20, 21 Gadolinium-based contrasting agents (GBCAs) (Figure 3) are
divided by their chemical structures and properties as linear or macrocyclic and ionic
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or non-ionic.19 The stability of the gadolinium complex from most to least are
macrocyclic, ionic linear, and non-ionic linear.19

Figure 3: Structures of Gd contrast agents
The stability of the GBCAs is determined based on how well the complex is able
to keep the Gd3+ ion in its cavity.19 Retaining the Gd3+ ion is crucial because it is a
toxic heavy metal. In recent years data has been presented that has rejected the safety
of GBCAs. It was hypothesized that the GBCAs were excreted from the body through
the kidneys in healthy patients; however, gadolinium has been shown to accumulate in
the tissue of patients who have gone through contrast MRI.22 Studies have shown that
Gd accumulates in the denate nucleus and globus pallidus of the brain, bone, skin, and
liver.22 Regardless of renal function Gd build-up is bound to occur, which is alarming
due to the toxic effects.

5

Due to the safety concerns of gadolinium it is important to develop safer
alternatives. A promising alternative is HP

129

Xe MRI. HP

129

Xe MRI has high

efficacy in imaging and is safe.23 Xe has already been used safely as a contrast media
for lung imaging via computed tomography (CT).24 While non-hyperpolarized xenon
produces a low intensity magnetic resonance signal, the process of hyperpolarizing
xenon uses polarized lasers to specifically excite the electrons of gaseous rubidium in
the presence of a magnetic field.23 When these excited atoms collide with xenon-129
atoms, they transfer their electron spin polarization to the nucleus of the xenon atom,
resulting in xenon having up to 75% of their magnetic spins aligned with the external
magnetic field.33 This technique, when combined with a MRI pulse sequence called
HyperCEST, increases the sensitivity of xenon-129 magnetic resonance signal a
billion fold, creating a molecular imaging technique that, in principle, has comparable
sensitivity to the state of the art technologies, such as positron emission tomography
(PET).17 Hyperpolarized Xe atoms when introduced into the human body do not
provide targeted imaging, so a supramolecular complex with an affinity tag is
necessary for regiospecific images to be produced. The purpose of this study was to
synthesize six ThT analogues that could potentially be used as the affinity tag in
various supramolecular complexes needed for HP

129

Xe MRI. The following chapter

describes the synthesis of these tags and presents a possible scheme for attaching them
to supramolecular hosts.
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CHAPTER 2

METHODS AND DISCUSSION

Thioflavin is a dye with a backbone composed of benzothiazole and
aminobenzoyl rings.12, 25 The synthesis of the majority of ThT analogues (Figure 4)
required the use of high temperatures, acidic solvents, cyclic benzoic acids, amino
groups, and lengthy reaction durations.

Figure 4: ThT analogues synthesized

7

Analogue
4 Intermediate
3
2
1

R
H
OCH3
H
OCH3

X
S
S
O
O

R’
NH2
NH2
NH2
NHCH3

Yield
74%
34%
69%
0.08%

Figure 5: General reaction conditions for ThT and yield
The synthesis of analogues 1, 2, 3, and 4 involved the condensation of the
amino phenol / benzothiol and 4-aminobenzoic acid in polyphosphoric acid at high
temperatures for 4 hours. (Figure 5) Analogue 4 was completed by monomethylating
the product of the condensation of the respective phenol and benzoic acid reagents via
reductive amination. The terminal amine was deprotonated by sodium methoxide,
reacted with paraformaldehyde and then reduced with sodium borohydride, in the
polar protic solvent methanol.
The low yield of analogue 1 is due to the methoxy being electron donating.
The electron donation makes the 4-amino-2-methoxybenzoic acid a poor electrophile.
The yield of analogue 3 is much better than analogue 1 even though the same benzoic
acid is used because sulfur is a far better nucleophile than oxygen.
Analogue 1 was a difficult synthesis resulting in a 0.08% yield of product. The
procedure followed was that of Jung et al.2 After careful inspection of 1H, 13C, and 2D NMR spectra, we concluded that the desired product, which contained a methoxy
8

group, was not synthesized by myself or Jung. Jung reported chemical shifts for the
methoxy in the 1H and 13C NMR as 2.90 and 30.26; respectively. Both shifts are more
upfield than expected. In 1H and
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C NMR a methoxy shift is expected to be in the

range of 3.3 – 3.8 ppm and 40 – 60 ppm; respectively. The amine protons were not
reported by Jung, which were extremely useful in the determination of the product’s
structure. The amine protons were at two very different chemical shifts in the 1H
NMR. One amine proton was observed at 4.18 ppm and the other at 11.54 ppm. Both
amine protons integrated to 1, which suggested that the protons were in two different
environments. After careful and methodical investigation, it was proposed that the
product synthesized was a N-substituted amine with a hydroxyl group on the aniline
and not the respective methoxy meta-substitution on the aniline (Figure 6).

Figure 6: Structure of Analogue 1. A was the synthesized product. B was the expected
product.
It is proposed that in the presence of PPA and at high temperatures, the oxygen
of the methoxy on the starting reagent, 4-amino-2-methoxybenzoic acid, is protonated.
The methyl group is now the leaving group which is then picked up by the amine of
another mole of benzoic acid.

9

Figure 7: Mechanism of ThT analogues 2,3 and 4
The mechanism of 2,3 and 4 (Figure 6) for ThT formation begins with the
protonation of the carbonyl oxygen followed by the nucleophilic addition of the amine
of the phenol / benzothiol to the carbonyl. The next step is a loss of water by the
hydroxyl group picking up a proton by the adjacent amine. The oxygen / sulfur then
attacks the reduced carbonyl C to form the benzo-oxazole / thiazole ring. The next step
is a second condensation where water is lost by the remaining hydroxyl group picking
up a proton. The final step is the deprotonation of the amine.
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Figure 8: Synthesis of analogues 5 and 6
The synthesis of analogue 5 (Figure 7) was the condensation of 4dimethylaminobenzoaldehyde and 2-amino-6-methoxybenzothiazole in anhydrous 2propanol with a catalytic amount of acetic acid for 18 hours. The one pot synthesis of
analogue 6 (Figure 7) was the condensation of 4-dimethylaminobenzoaldehyde and 2aminothiophenol in DMSO for 2 hours.

11

Figure 9: Mechanism of analogue 5
The mechanism of 5 begins with the nucleophilic addition of the amine to the
carbonyl. The base then deprotonates the amine as the oxygen acting as a Bronsted
base picks up a proton from water. This happens twice. Finally, to form a double bond
an E1 reaction occurs, water is eliminated as the by-product which results in a
carbocation. The extra pair of electrons on nitrogen are then donated to create a double
bond with the carbon.
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The ThT analogues 1-6 were synthesized. Prior to coupling these ThT analogs to
the supramolecular complexes to be used in conjunction with HP

129

Xe MRI, binding

studies between the analogs and beta-amyloid fibrils should be done to determine the
association constant for each analogue.

The binding studies would require the

formation of beta-amyloid fibrils, which are synthesized through nucleation and
growth phases.28 The fibrils are formed in low pH aqueous solutions at 37 oC with
agitation.29 The development of the protein aggregates can be assessed by small angle
light scattering (SALS) and light transmittance measurements.30 The fluorescence of
ThT allows for the binding association constants of the analogs to be determined with
the use of a spectrofluorophotometer.31 The excitation wavelength for each ThT
analogue will vary which requires for individual measurements obtained from a UVVIS spectrophotometer. The literature value of the excitation wavelength for the
standard ThT molecule is 440 nm.32
The binding studies will give insight on the potential efficacy of the ThT
analogues conjugated to the supramolecular complexes used in HP

129

Xe MRI. The

greater the association constant, the greater the affinity the ThT analogues have
towards beta amyloid fibrils.
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Figure 10: Synthesis of Rotaxane-ThT probe
After synthesizing the ThT analogues and conducting the binding studies to
determine the association constants, the following step is the synthesis of the Xe
biosensor. The synthesis of the biosensor, completed by lab mate Ashvin Fernando,
(Figure 9, provided by A. Fernando) begins with the acylation of a ThT analogue with
a 6-carbon alkyl acyl chloride chain to form an amide bond. Following the acylation,
the ThT complex undergoes a SN2 reaction with furan protected malemide. Finally, in
a one pot, high temperature environment, the malemide complex and the cyclodextrin
cage along with an anthracene linker are combined. The anthracene and malemide
undergo a Diels-Alder reaction; and, the cyclodextrin does a self-inclusion with the
affinity tag and linker complex to become an interlocked molecule.
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Experimental
The following protocols were used to synthesize all known compounds.
Reagents and Solvents
The following reagents and solvents were used: 4-amino-2-methoxybenzoic acid, 2aminophenol, polyphosphoric acid, sodium carbonate, sodium sulfate, ethyl acetate,
sodium

methoxide,

paraformaldehyde,

methanol,

sodium

borohydride,

4-

dimethylaminobenzaldehyde, 2-aminothiophenol, dimethyl sulfoxide, 4-aminobenzoic
acid, 2-aminothiophenol, sodium hydroxide, acetic acid, 2-propanol, and deuterated
chloroform.
All reagents and solvents were purchased from Fisher Scientific, Sigma Aldrich, and
Cambridge Isotopes Laboratories. All materials with the exception of 2-propanol
were used without alteration. 2-propanol was dried with 3 Å molecular sieves for 48
hours before use.
Instrumentation
1

H and

13

C NMR spectra were acquired from either a Bruker Avance 300 MHz

spectrometer or Bruker Avance 400 MHz spectrometer. Flash column chromatography
was completed using Teledyne ISCO CombiFlash Rf with Redisep silica cartridges.
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Synthesis of 2-(benzo[d]oxazol-2-yl)-5-(methylamino)phenol, 1

2-aminophenol (0.57 g, 5 mmol), 4-amino-2-methoxybenzoic acid (0.83 g, 5mmol)
and polyphosphoric acid were heated for 4 hours at 200℃. The reaction mixture
cooled overnight. After, 10% sodium carbonate (100 mL) was poured into the mixture.
An extraction was done using ethyl acetate which was then washed with brine and
dried over sodium sulfate. The crude product was purified using column
chromatography and the product was obtained (0.010 g, 0.08%). NMR data was
consistent with reported values.2
1H

NMR (300 MHz, CDCl3) δ 11.54 (s, 1H), 7.78 (d, J = 9.2 Hz, 1H), 7.63 (dd, J =

6.9, 2.3 Hz, 1H), 7.53 (dd, J = 7.0, 2.3 Hz, 1H), 7.35 – 7.27 (m, 2H), 6.26 (s, 1H), 6.23
(d, J = 2.3 Hz, 1H), 4.18 (s, 1H), 2.90 (s, 3H).
13C

NMR (101 MHz, CDCl3) δ 163.69, 160.60, 153.65, 148.74, 140.36, 128.04,

124.35, 123.87, 118.12, 109.97, 105.55, 99.94, 97.88, 30.01.
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Spectrum 1- 1H NMR of Analogue 1
17

Spectrum 2 – 13C NMR of Analogue 1
18

Synthesis of 4-(benzo[d]oxazol-2-41) aniline, 2

4-aminobenzoic acid (0.83 g, 6 mmol), 2-aminophenol (0.54 g, 5 mmol), and
polyphosphoric acid (20 g) were heated for 4 hours at 200℃. The reaction mixture
cooled overnight. The mixture was then poured into 10% sodium carbonate (100 mL)
and extracted with ethyl acetate. The extraction was concentrated, and the product was
obtained by recrystallization with methanol and water (0.730 g, 69%).
1H

NMR (400 MHz, CDCl3) δ 8.06 (d, J = 8.7 Hz, 2H), 7.71 (dd, J = 6.6, 2.6 Hz,

1H), 7.52 (dd, J = 6.7, 2.5 Hz, 1H), 7.34 – 7.27 (m, 2H), 6.76 (d, J = 8.7 Hz, 2H), 4.05
(s, 2H).
13C

NMR (101 MHz, CDCl3) δ 163.90, 150.66, 149.81, 142.43, 129.57, 124.42,

124.36, 119.43, 117.01, 114.81, 110.36.
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Spectrum 3- 1H NMR of Analogue 2
20

Spectrum 4- 13C NMR of Analogue 2
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Synthesis of 2-(2’ methoxy -4’-aminophenyl) benzothiazole, 3

2-aminothiophenol (0.58 g, 5 mmol), 4-amino -2-methoxybenzoic acid (0.83 g, 5
mmol), and polyphosphoric acid (8.2 g) were heated for 4 hours at 100℃. The mixture
was cooled overnight. After, the mixture was poured into water and a precipitate was
observed. Sodium hydroxide pellets were added until the pH was 7. The precipitate
was filtered, and the product was obtained (0.44 g, 34%). NMR data was consistent
with reported values.2
1H

NMR (300 MHz, CDCl3) δ 8.32 (d, J = 8.5 Hz, 1H), 8.00 (d, J = 7.6 Hz, 0H), 7.87

(d, J = 7.2 Hz, 1H), 7.44 (ddd, J = 8.2, 7.2, 1.3 Hz, 1H), 7.30 (ddd, J = 8.2, 7.2, 1.2
Hz, 1H), 6.42 (dd, J = 8.5, 2.2 Hz, 1H), 6.31 (d, J = 2.1 Hz, 1H), 4.00 (s, 3H).
13C

NMR (75 MHz, CDCl3) δ 163.94, 158.98, 152.42, 150.42, 135.65, 131.08,

125.76, 123.90, 122.14, 121.14, 113.26, 108.09, 97.64, 55.63.
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Spectrum 5- 1H NMR of Analogue 3

23

Spectrum 6- 13 C NMR of Analogue 3
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Synthesis of 2-(4-methylaminophenyl) benzothiazole, 4

2-aminothiophenol (2.5 g, 20 mmol), 4-aminobenzoic acid (2.8 g, 20 mmol) and
polyphosphoric acid (20 g) were heated for 4 hours at 200℃. The mixture cooled
overnight. The mixture was then poured into sodium carbonate and the precipitate was
filtered. The solid was purified by recrystallization with methanol and water (3.35 g,
74%).
1H

NMR (400 MHz, CDCl3) δ 8.00 (d, J = 8.1 Hz, 1H), 7.91 (dt, J = 8.6, 2.0 Hz, 2H),

7.85 (d, J = 7.6 Hz, 1H), 7.45 (ddd, J = 8.3, 7.2, 1.3 Hz, 1H), 7.32 (ddd, J = 8.3, 7.2,
1.2 Hz, 1H), 6.74 (dt, J = 8.6, 2.0 Hz, 2H), 4.04 (s, 2H).
13C

NMR (101 MHz, CDCl3) δ 168.67, 154.31, 149.40, 134.68, 129.32, 126.23,

124.62, 124.05, 122.62, 121.56, 114.93.
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After, the purified solid (0.24 g, 1 mmol) was dissolved in methanol (20 mL); and,
sodium methoxide (0.054 g, 1 mmol) and paraformaldehyde (0.026 g, 1 mmol) were
added to the solution. The reaction mixture was refluxed for 2 hours. Once complete
the reaction mixture was cooled to 0℃ and sodium borohydride (0.038 g, 1 mmol)
was added slowly. The mixture was refluxed for 1 hour, poured into 0℃ water, and
then extracted with ethyl acetate. The extracts were dried over sodium sulfate and
filtered. The product was obtained by chromatography (0.028 g, 11%).
1H

NMR (300 MHz, CDCl3) δ 8.02 (d, J = 8.1 Hz, 1H), 7.96 (d, J = 8.7 Hz, 2H), 7.84

(d, J = 7.9 Hz, 1H), 7.45 (ddd, J = 8.3, 7.2, 1.3 Hz, 1H), 7.32 (ddd, J = 8.3, 7.3, 1.2
Hz, 1H), 6.66 (d, J = 8.7 Hz, 2H), 2.92 (s, 3H).
13C

NMR (101 MHz, CDCl3) δ 169.09, 151.89, 129.43, 129.37, 126.32, 124.57,

122.29, 121.53, 114.94, 112.23, 30.48.
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Spectrum 7- 1H NMR of Analogue 4 Intermediate
27

Spectrum 8- 13C NMR of Analogue 4 Intermediate
28

Spectrum 9- 1H NMR of Analogue 4
29

Spectrum 10- 13C NMR of Analogue 4
30

Synthesis of N-[[ 4-(Dimethylamino) phenyl] methylene]-6-methoxy-2–
benzothiazoleamine, 5

2-amino-6-methoxybenzothiazole (0.36 g, 2 mmol), 4-dimethylaminobenzaldehyde
(0.30 g, 2 mmol) and anhydrous 2-propanol (20 mL) were added to a flask. Acetic
acid (0.11 mL) was added dropwise to the reaction and it was refluxed for 18 hours. It
was then allowed to cool to room temperature and the product was obtained through
filtration (0.441 g, 71%). NMR data was consistent with reported values.27
1H

NMR (400 MHz, CDCl3) δ 8.81 (s, 1H), 7.90 (d, J = 8.4 Hz, 2H), 7.81 (d, J = 8.9

Hz, 1H), 7.27 (d, J = 2.6 Hz, 1H), 7.03 (dd, J = 8.9, 2.6 Hz, 1H), 6.73 (d, J = 9.0 Hz,
2H), 3.88 (s, 3H), 3.11 (s, 6H).
13C

NMR (101 MHz, CDCl3) δ 170.83, 164.73, 157.38, 153.82, 146.45, 135.34,

132.51, 123.22, 122.80, 115.16, 111.66, 104.75, 55.95, 40.26.

31

Spectrum 11- 1H NMR of Analogue 5
32

Spectrum 12- 13C NMR of Analogue 5
33

Synthesis of 2-( 4- Dimethylaminophenyl) benzothiazole, 6

4 – dimethylaminobenzaldehyde (0.75 g, 5mmol), 2- aminothiophenol (0.69 g, 6
mmol) and DMSO (10 mL) were put in a flask and refluxed for 2 hours. The reaction
mixture was then left to cool to room temperature. Once at room temperature water
was added to the mixture and the precipitate was separated by filtration. A
recrystallization with methanol and water produced the final product (0.805 g, 63%).
NMR data was consistent with reported values.26
1H

NMR (300 MHz, CDCl3) δ 8.04 – 7.88 (m, 3H), 7.84 (d, J = 7.8 Hz, 1H), 7.44

(ddd, J = 8.3, 7.3, 1.3 Hz, 1H), 7.30 (ddd, 8.3, 7.3, 1.3 Hz, 1H), 6.75 (d, J = 9.0 Hz,
2H), 3.06 (s, 6H).
13C

NMR (101 MHz, CDCl3) δ 168.94, 154.53, 152.32, 134.67, 129.01, 126.11,

124.32, 122.41, 121.52, 121.48, 111.83, 40.33.

34

Spectrum 13- 1H NMR of Analogue 6

35

Spectrum 14 – 13C NMR of Analogue 6

36
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